Outlook Therapeutics
OTLK
66 hedge funds and large institutions have $9.56M invested in Outlook Therapeutics in 2025 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 16 increasing their positions, 18 reducing their positions, and 17 closing their positions.
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
11% more capital invested
Capital invested by funds: $8.64M → $9.56M (+$915K)
5% more funds holding
Funds holding: 63 → 66 (+3)
3.92% less ownership
Funds ownership: 21.72% → 17.8% (-3.9%)
11% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 18
24% less call options, than puts
Call options by funds: $31K | Put options by funds: $41K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$660K |
| 2 |
Morgan Stanley
New York
|
+$616K |
| 3 |
Millennium Management
New York
|
+$540K |
| 4 |
Squarepoint
New York
|
+$248K |
| 5 |
Renaissance Technologies
New York
|
+$169K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.44M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.05M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$488K |
| 4 |
State Street
Boston,
Massachusetts
|
-$323K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$300K |
OTLK Hedge Fund Activity: Q2 2025 in Review
66 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2025, worth a combined $9.56M — up 11% from $8.64M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new OTLK positions and 17 closed out — a net gain of 3 holders — while 16 added to existing stakes and 18 trimmed.
The largest buyer was Vanguard Group, adding an estimated $660K. The largest seller was BlackRock, cutting an estimated $1.44M.
- 66 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2025, up from 63 in Q1 2025.
- Funds reported $9.56M of Outlook Therapeutics stock for Q2 2025, up 11% quarter-over-quarter.
- 20 funds opened new Outlook Therapeutics positions in Q2 2025 and 17 closed out, a net change of +3 holders.
- The largest Outlook Therapeutics buyer in Q2 2025 was Vanguard Group, an estimated $660K added.
- The largest Outlook Therapeutics seller in Q2 2025 was BlackRock, an estimated $1.44M sold.
Based on aggregated 13F filings for Q2 2025.